Buprenorphine

Major

Buprenorphine Enzalutamide Xtandi Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Eplerenone Inspra Explained Reduced efficacy of diuretics Details Buprenorphine Eribulin Halaven Explained An increased risk of QT interval prolongation Details Buprenorphine Erythromycin Erythrocin Stearate Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Escitalopram Lexapro Explained An increased risk of QT interval prolongation and an increased risk of serotonin syndrome Details Buprenorphine Esketamine Spravato Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Eslicarbazepine Acetate Aptiom Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Estazolam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Eszopiclone Lunesta Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Ethacrynic Acid Edecrin Explained Reduced efficacy of diuretics Details Buprenorphine Ethchlorvynol Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Ethopropazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Ethylmorphine Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Etozolin Explained Reduced efficacy of diuretics Details Buprenorphine Etrasimod Velsipity Explained Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Buprenorphine Etravirine Intelence Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Famotidine Calmicid An increased risk of QT interval prolongation Details Buprenorphine Felbamate Felbatol An increased risk of QT interval prolongation Details Buprenorphine Fenfluramine Explained An increased risk of serotonin syndrome (hypertension, tachycardia, hyperthermia, myoclonus, mental status changes) Details Buprenorphine Fentanyl Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Fesoterodine Toviaz Explained An increased risk of paralytic ileus Details Buprenorphine Fexinidazole Explained An increased risk of QT interval prolongation Details Buprenorphine Fingolimod Gilenya Explained An increased risk of QT interval prolongation Details Buprenorphine Flavoxate Explained An increased risk of paralytic ileus Details Buprenorphine Flecainide Tambocor® An increased risk of QT interval prolongation Details Buprenorphine Flibanserin Addyi Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Flunitrazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Fluoxetine RECONCILE Explained An increased risk of QT interval prolongation and an increased risk of serotonin syndrome Details Buprenorphine Fluphenazine Explained An increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Flurazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Fluspirilene Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Fluvoxamine Explained An increased risk of serotonin syndrome, increased buprenorphine exposure and an increased risk of buprenorphine-related adverse e... Details Buprenorphine Formoterol Perforomist Explained An increased risk of QT interval prolongation Details Buprenorphine Fosamprenavir Lexiva Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Fosaprepitant Emend Injection Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Foscarbidopa Explained An increased risk of CNS depression Details Buprenorphine Foscarnet Foscavir Explained An increased risk of QT interval prolongation Details Buprenorphine Fosfomycin Contepo Explained An increased risk of QT interval prolongation Details Buprenorphine Foslevodopa Explained An increased risk of CNS depression Details Buprenorphine Fosnetupitant Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details